Clinical Trial Update: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating obinutuzumab plus ICE chemotherapy for refractory or recurrent CD20-positive mature non-Hodgkin lymphoma is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Cd20-positive Lymphoblastic Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mediastinal B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: New York Medical College | Conditions: Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Status: RECRUITING